In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody

Hybridoma and Hybridomics

Volumn 21, Issue 6, 2002, Pages 463-468

  Carr, Adriana ^a   Mesa, Circe ^a   Arango, María Del Carmen ^b   Vázquez, Ana María ^a   Fernández, Luis Enrique ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b National Oncology and Radiobiology Institute   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14F7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY;

ANIMALIA; EQUUS CABALLUS; MURINAE;

EID: 0037716989     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685902321043990     Document Type: Article

References (28)

1. Hakomori S.H: Tumor associated carbohydrate antigens. Ann Rev Immunol 1984;2:103-126.
2. Hougton AN, Mintzer D, Cordon-Cardo C, Welt B, Fliegel S, Vadhart S, Carswell E, Melaned MR, Oettgen, HF, and Old LJ: Mouse monoclonal antibody IgG3 antibody detecting GD3 ganglioside. A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985;82:1242-1246.
3. Irie R, and Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986,83:8694-8698.
4. Zhang H, Zhang S, Nai-kong V, Cheung V, Ragupathi G. and Livingston PO: Antibodies against GD2 ganglioside can eradicate syngenic cancer micrometastases. Cancer Res 1998,58:2844-2049.
5. Kushner BH, Kramer K, and Cheung NK: Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-4194.
6. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, and Relsfeld RA: Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989,49:2857-2861.
7. Livingston PO, and Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997;45:10-19.
8. Ravindranath MH, Gonzáles AM, Nishimoto K, Tam WY, Sah D, and Morton DL: Immunology of gangliosides. Indian J Exp Biol 2000;38:301-312.
9. Leeden RW, and Yu RK: Chemistry and analysis of sialic acid. In: Rosemberg A and Schegtrund CL (Eds.). Biological Role of Sialic Acid. New York, Plenum Press, 1976, pp. 1-4-8.
10. Kawai T, Kato A, Higashi H, Kato S, and Naiki M: Quantitative determination of Nglycolyl-neuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor associated sialic acid by gas chromatography -mass spectrometry. Cancer Res 1991;51:1242-1246.
11. Koda T, Shimosakoda T, Asaoka H, Nishinaka S, Tamura I, Nakaba H, and Matsuda H: Detection of Hanganutziu-Deicher antigen in patients with hepatocellular carcinoma. Intern Hepatol Commun 1994;2:310-315.
12. Furukawa K, Yamaguchi H, Oettgen, HF, Old, LJ, Lloyd, and KO: Analysis of the expression of N-Glycolylneuraminic Acid-containing Gangliosides in Cell and Tissues using Two Human Monoclonal Antibodies. J Biol Chem 1988;263:18507-18512.
13. Vázquez AM, Alfonso M, Karlsson A, Carr A, Barroso O, Fernández LE, Rengifo E, Lanio ME, Alvarez, C, Zeuthen J, and Pérez R: Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid containing gangliosides that also recognizes sulfated glycolipids. Hybrid 1995;14:551-556.
14. Marquina G, Waki H, Fernández LE, Kon K, Carr A, Valiente O, Pérez R, and Ando S: Gangliosides Expressed in Human Breast Cancer. Cancer Res 1996;56;5165-5171.
15. 1 monoclonal antibody specificFor N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19:241-247.
16. Higashi H, Naiki M, Matuo S, and Okouchi K: Antigen of "serum sickness" type Heterophile antibodies in pathologic human sera: identification as gangliosides with N-Glycolylneuraminic acid. Biochem Biophys Res Commun 1977;79:388-395.
17. Kasukawa R, Kano K, Bloom ML, and Milgrom F: Heterophile antibodies in pathologic human sera resembling antibodies stimulated by foreign species sera. Clin Exp Immunol 1976;25:122-132.
18. Herlyn DM, and Koprowsky H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 1981;26:769-774.
19. Schmid I, Uttenbogaart CH, and Giorgy JV: Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry 1994;15:12-20.
20. 3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res 1988;48:5680-5685.
21. Broun Go JR, Petruska PJ, Hiramoto RN, and Cohen HJ: Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. Cancer Treat Rep 1982,;66:237-242.
22. Chapman PB. Lonberg M, and Houghton AN: Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res 1990;50:1503-1509.
23. Cheung NK. Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, and Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-1440.
24. Rosales C, Jeglum KA, Obrocka M, and Steplewski Z: Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement. Cell Immunol 1988;115:420-428.
25. Matsuoka S, Asano Y, Sano K, Kishimoto H, Yamashita I, Yorifuji H, Utsuyama M, Hirokawa K, and Tada T: A novel type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody without Participation of complement. J Exp Med 1995;181:2007-2015.
26. Bhat NM, Bieber MM, and Teng NNH: Cytotoxicity of murine B lymphocytes induce by human VH4-34(VH4.21) gene-encoded monoclonal antibodies. Clin. Immunol. Immunopath 1997;84;283-289.
27. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, Lobuglio AF, Wheeler RH, Cooper MR, and Waksal HW: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19;3234-3243.
28. Livingston RB, and Esteva FJ: Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug? Oncologist, 2001;6:315-316.